Cell and Gene Therapy Market Size, Share & Trends Analysis Report By Type (Cell Therapy, CAR-T Cell Therapy, CAR-NK, B-Cell, Others, Viral, Non-viral), By Application (Oncology, Dermatology, Musculoskeletal, Immunology, Neurology, Others), By Manufacturer (Biopharmaceutical & Biotechnology Companies, Pharmaceutical Companies, CDMOs/CMOs, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Cell and Gene Therapy Market Dynamics

Market Drivers

Increasing Commercial Reinvestment from High-revenue Gene Therapies and Rising Demand for Scalable Non-Viral Gene Delivery Platforms Drives Market

The strong revenue generation of newly commercialized gene therapies is creating a self-reinforcing investment cycle that drives market expansion. Successful products enable companies to fund additional pipeline programs, manufacturing infrastructure, and next-generation platform development. In 2025, Sarepta Therapeutics indicated that Elevidys was expected to surpass USD 2 billion in annual revenue, supporting investment across more than 40 programs involving gene therapy, gene editing, and RNA technologies. This commercialization-led capital reinvestment is accelerating innovation and expanding therapeutic pipelines.

The growing demand for non-viral gene delivery technologies is emerging as a key market driver for cell and gene therapies. Traditional viral vectors face limitations related to manufacturing capacity, cost, and payload size, prompting developers to invest in alternative delivery approaches such as lipid nanoparticles (LNPs), polymer-based carriers, and engineered nanoparticles. Multiple clinical-stage programs advanced the use of LNP-enabled gene editing and genetic medicine delivery beyond liver-targeted applications. As developers seek scalable and cost-efficient manufacturing solutions capable of supporting larger patient populations, investment and development activity in non-viral delivery platforms is increasing, contributing to cell and gene therapy market growth.

Market Restraints

Increasing Regulatory and Safety-related Clinical Holds and Limited Availability of Viral Vector Manufacturing Capacity Restrain Market Expansion

The growing number of regulatory reviews, safety concerns, and clinical trial holds is limiting the pace of cell and gene therapy development. As more advanced therapies enter late-stage clinical trials and commercialization, regulatory agencies are intensifying scrutiny of long-term safety, manufacturing consistency, and treatment efficacy. These regulatory hurdles create uncertainty for developers and investors and slow the commercialization of innovative therapies, thereby restraining cell and gene therapy market growth.

Major FDA Regulatory Undertakings in Cell and Gene Therapy Market, 2025

The limited availability of viral vector manufacturing capacity remains a significant restraint for the market. Most approved gene therapies rely on adeno-associated virus (AAV) and lentiviral vectors, which require highly specialized production infrastructure and complex quality testing. According to the American Society of Gene & Cell Therapy (ASGCT), more than 2,000 gene, cell, and RNA therapies were in active development globally in 2025, intensifying demand for vector production. The resulting capacity constraints increase manufacturing costs and delay clinical and commercial supply, thereby restraining cell and gene therapy market growth.

Market Opportunities

Emergence of Off-the-Shelf Allogeneic Cell Therapies and Expansion of Gene Therapies for Ultra-Rare Genetic Disorders Offer Growth Opportunities for Market Players

The development of allogeneic off-the-shelf cell therapies is creating a major opportunity for the cell and gene therapy market by overcoming the limitations of patient-specific manufacturing. Unlike autologous therapies, allogeneic products can be manufactured in bulk, reducing production costs and treatment wait times. According to the ASGCT Q1 2026 landscape report, more than 430 allogeneic cell therapy clinical programs were active globally. As companies advance universal donor cell platforms for oncology and autoimmune diseases, large-scale commercialization opportunities are expected to expand significantly across global markets.

The growing focus on ultra-rare genetic disorders presents a significant opportunity for the cell and gene therapy market. Advances in platform technologies are enabling developers to create therapies for diseases affecting only a few hundred patients worldwide, which were previously considered commercially unviable. The FDA supported multiple individualized and ultra-rare disease gene therapy programs under accelerated regulatory pathways. The increasing use of modular vector platforms and precision genetic medicine approaches is creating new revenue opportunities while addressing highly underserved patient populations.

Market Challenges

Long-term Patient Monitoring and Limited Availability of Specialized Treatment Centers Challenges Market Growth

Cell and gene therapies are designed to provide long-lasting or potentially curative outcomes, creating challenges in assessing long-term safety and durability. Developers are often required to conduct patient follow-up studies extending beyond 10–15 years to monitor treatment persistence and adverse events. Managing patient retention, data collection, and outcome tracking across extended periods increases operational complexity and delays the generation of comprehensive clinical evidence required for broader market adoption.

The administration of cell and gene therapies often requires highly trained clinical teams, advanced laboratory capabilities, and specialized healthcare facilities. However, the number of certified treatment centers remains limited in many countries. Patients frequently need to travel long distances to access treatment, creating logistical and financial burdens. This concentration of expertise in select institutions restricts patient access, slows therapy adoption, and poses a significant challenge to broader market expansion.

Cell And Gene Therapy Market Segmentation Analysis

By Type

Based on type, cell therapy is projected to grow at a CAGR of 25.24% during the forecast timeframe due to expanding adoption of allogeneic cell therapies, increasing development of immune-reset therapies for autoimmune diseases, and growing commercialization of off-the-shelf cell products. These innovations reduce manufacturing complexity, improve treatment accessibility, and broaden applications beyond oncology into larger chronic disease populations.

The gene therapy segment is expected to grow at a CAGR of around 25.08% during the forecast period, owing to rising utilization of in vivo gene-editing platforms, increasing development of therapies for ultra-rare monogenic disorders, and advancements in non-viral delivery technologies. These factors enhance therapeutic precision, improve scalability, and expand opportunities across previously underserved genetic disease indications.

By Application

In 2025, oncology accounted for a share of 61.33% in the cell and gene therapy market, by application. This is due to strong clinical validation of CAR-T therapies, increasing use of personalized tumor-targeting approaches, and extensive investment in hematological malignancy treatment pipelines. Established reimbursement pathways and higher patient demand further support for oncology's dominant market position.

The dermatology segment is expected to grow at a CAGR of 24.57% during the forecast period, driven by increasing development of gene therapies for rare inherited skin disorders, growing adoption of topical gene-delivery platforms, and rising clinical success in treating monogenic dermatological conditions. These advancements are expanding therapeutic options beyond conventional symptom-management approaches.

By Manufacturer

By manufacturer, biopharmaceutical & biotechnology companies accounted for a share of 41.81% in 2025 due to ownership of proprietary gene-editing platforms, strong intellectual property portfolios, and extensive late-stage clinical pipelines. Their ability to secure funding, conduct global trials, and commercialize innovative therapies strengthens their leadership across the cell and gene therapy value chain.

The CDMOs/CMOs segment is expected to grow at a CAGR of 25.11% during the forecast period, driven by increasing outsourcing of viral vector production, rising demand for specialized cell processing capabilities, and growing need for GMP-compliant manufacturing infrastructure. These organizations enable developers to accelerate commercialization while minimizing capital-intensive facility investments.

Cell And Gene Therapy Regional Outlook

North America Cell and Gene Therapy Market

North America: Market Dominance Led by Strong Commercial Manufacturing Facilities and Extensive Newborn Genetic Screening Programs

The North America cell and gene therapy market accounted for the largest regional share of 51.73% in 2025, driven by its concentration of commercial manufacturing facilities, specialized treatment centers, and advanced reimbursement frameworks. The region hosts the majority of globally approved cell and gene therapies and possesses the highest density of accredited CAR-T treatment sites. Strong integration between academic medical centers, genomic medicine programs, and biotechnology innovation hubs further accelerates therapy adoption.

US Cell and Gene Therapy Market

The US cell and gene therapy market was valued at USD 12.46 billion in 2025, driven by commercial cell and gene therapy deployment and rare disease treatment infrastructure. According to the FDA, the US accounts for the largest share of global cell and gene therapy approvals and clinical development programs. The presence of extensive newborn genetic screening programs, advanced genomic testing networks, and more than 200 authorized cell therapy treatment centers supports early patient identification and therapy accessibility.

Canada Cell and Gene Therapy Market

The cell and gene therapy market in Canada was valued at USD 1.70 billion in 2025. The growth is driven by increasing focus on genomic medicine and population-based genetic research initiatives. Canada’s All for One Precision Health Partnership, one of the world's largest pediatric precision health programs, is accelerating the integration of genomics into clinical care. Its publicly funded healthcare system is expanding access to genetic testing and rare disease diagnostics.

Asia Pacific Cell and Gene Therapy Market

Asia Pacific: Fastest Growth Driven by Increasing Investments in Advanced Biomanufacturing Infrastructure and Growth Genetic Disease Research

The Asia Pacific cell and gene therapy market is expected to grow at a CAGR of 25.86% during the forecast period, showcasing the fastest regional growth. Expansion is driven by government-backed genomics initiatives, increasing investments in advanced biomanufacturing infrastructure, and growing adoption of precision medicine. The region is rapidly strengthening domestic cell and gene therapy capabilities through dedicated innovation hubs and translational research centers.

China Cell and Gene Therapy Market

The China cell and gene therapy market was valued at USD 1.48 billion in 2025, supported by its leadership in clinical-stage cell therapy development and large-scale genomic research initiatives. According to the ASGCT clinical landscape, China accounts for one of the world's largest shares of active cell therapy clinical trials, particularly in oncology. The country’s substantial patient pool streamlined clinical development pathways.

India Cell and Gene Therapy Market

The India cell and gene therapy market was valued at USD 791.28 million in 2025, supported by increasing investment in indigenous genomic medicine capabilities and rare disease diagnostics. The GenomeIndia Project has successfully sequenced over 10,000 genomes from diverse populations, creating a foundational resource for precision medicine and genetic disease research. Expanding genomic datasets are improving understanding of population-specific disease variants, supporting future development of localized gene therapies.

Japan Cell and Gene Therapy Market

The Japan cell and gene therapy market was valued at USD 977.46 million in 2025, supported by its globally recognized regenerative medicine framework and accelerated approval pathways. Strong collaboration between academic research institutions, hospitals, and biotechnology companies continues driving innovation in iPSC-based therapies, regenerative medicine applications, and advanced cell therapy development, reinforcing Japan's position as a major innovation hub in the region.